EntreMed (ENMD)
EntreMed Liabilities: 9.582M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ENMD Liabilities Rankings
| Overall | 92nd percentile | 316 of 4384 |
| Sector | 78th percentile | 109 of 504 in Healthcare |
| Industry | 75th percentile | 40 of 160 in Biotechnology |
ENMD Liabilities Range, Past 5 Years
| Minimum | 0.7041M | Dec 2011 |
| Maximum | 26.12M | Dec 2007 |
| Average | 12.83M |
About Total Liabilities
Liabilities are obligations of a company arising from past transactions or events which are expected to reduce assets when they are settled.
Total liabilities is a line item on the balance sheet.
Learn More
You may also be interested in these ENMD related companies
ENMD News
EntreMed Regains Nasdaq Compliance With Shareholders' Equity Listing Requirement
May 10, 7:01AM Benzinga
May 10, 7:01AM Benzinga
$ENMD forms bearish "Top Triangle" chart pattern. http://stks.co/3fNf
about 25 days ago by RecogniaEvents
about 25 days ago by RecogniaEvents
$ENMD filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/338o
about 67 days ago by MarketBrief
about 67 days ago by MarketBrief
$ENMD filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/31Yb
about 68 days ago by MarketBrief
about 68 days ago by MarketBrief
EntreMed (ENMD) Enters $9.3M of Strategic Financing, Two Board Members Resign
Feb 06, 7:01AM Street Insider
Feb 06, 7:01AM Street Insider
Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors
Feb 06, 7:00AM PR Newswire
Feb 06, 7:00AM PR Newswire
$ENMD 200 Day SMA Cross - Price crossed above 200 day SMA (2.2611). Confirmed by volume.
about 116 days ago by TradeIdeasQuant
about 116 days ago by TradeIdeasQuant
$ENMD 200 Day SMA Cross - Price crossed above 200 day SMA (2.3135). Confirmed by volume.
about 120 days ago by TradeIdeasQuant
about 120 days ago by TradeIdeasQuant
$ENMD 200 Day SMA Cross - Price crossed below 200 day SMA (2.3135). Confirmed by volume.
about 120 days ago by TradeIdeasQuant
about 120 days ago by TradeIdeasQuant
Small cancer bios hot today. $SNSS starting. $MSHL, $AGEN, $ENMD already went.
about 124 days ago by GarethSoloway
about 124 days ago by GarethSoloway
EntreMed (ENMD) Enters $10M in Purchase Agreements; Will Issue Convertible Notes
Jan 23, 7:04AM Street Insider
Jan 23, 7:04AM Street Insider
Amazing how on a split-adjusted basis the all-time high for $ENMD is over $1000/share. How the mighty have fallen.
about 130 days ago by bradloncar
about 130 days ago by bradloncar
$enmd $spx Been noticing of late that entremed has been up on days that mkt gets killed. No position on $enmd.
about 250 days ago by jerchess
about 250 days ago by jerchess
$ENMD $2.05 OS 11,597,490 amn'd prospectus to offer 107,103 cmn shs (1% dilution) for sale from time to time
about 318 days ago by canarionyc
about 318 days ago by canarionyc
$ENMD $2.60 Mkt Cap $30,105,321 offering $7,500,000 for sale from time to time (25% dilution)
about 335 days ago by canarionyc
about 335 days ago by canarionyc
$VRUS $CYTX $ARIA $ENMD $EXEL A number of biotech companies have new hepatitis C treatments http://equities.com http://stk.ly/ju4LWv $$
about 355 days ago by micstockwell
about 355 days ago by micstockwell
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ENMD | 1.99 | +0.01 | +0.51% | 24.20M |
| ENL | 21.44 | -0.12 | -0.56% | 7.762B |
| ENI | 17.84 | +0.22 | +1.25% | 11.65B |
| ENH | 39.26 | -0.09 | -0.23% | 1.692B |
| ENG | 1.73 | -0.03 | -1.70% | 46.05M |
| ELNK | 8.19 | +0.03 | +0.37% | 869.61M |
| ELN | 14.30 | +1.11 | +8.42% | 8.428B |
| ELLO | 5.65 | -0.20 | -3.42% | 60.91M |
| ELGX | 14.27 | +0.19 | +1.35% | 830.23M |
| EL | 54.96 | -0.13 | -0.24% | 21.31B |
